With patent bluffs, rivalry from generics to battle with, and mounting tension from medical services players, insurance agencies and states to give essential items at reasonable expenses – the drug business might be in for a few difficult stretches ahead. The cutthroat scene of the US$300 billion drug industry is evolving quickly, with concentration slowly moving from drug research organizations ...
